SPIRIVA® RESPIMAT®
For Asthma
Overview
Product overview
SPIRIVA® RESPIMAT® is indicated as a maintenance bronchodilator treatment and for reduction of exacerbation in adult patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and for the reduction of exacerbations.
Product Key Facts
Indications
Maintenance treatment of patients with COPD (including chronic bronchitis and emphysema) and reduction of exacerbations.
As an add-on maintenance bronchodilator treatment in patients aged 6 year and older with severe asthma who remain symptomatic on treatments that include an inhaled corticosteroid in a combination with other controller medication.
Active ingredient
Tiotropium
Legal category
Prescription only medicine
Concentration
2.5 micrograms per puff
Administration form
Oral inhalation
Dosage form
Inhalation solution
Pack sizes
Single pack: one cartridge of 4.0
ml and one RESPIMAT® inhaler
Reference
-
SPIRIVA® RESPIMAT® Solution for Inhalation, approved package insert. 20160610. Approved 11/2018.
